Principal Scientist - DMPK

Bristol-Myers Squibb
0 reviews

Posted on: 23 Jan 2021

Princeton, NJ

Apply on Company site Save this job

Job Description

At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.

Position Summary:

We are seeking a highly enthusiastic, self-motivated, exceptional scientist to join our Drug Metabolism and Pharmacokinetic (DMPK) Group as a Principal Scientist at our Princeton, NJ site. The role is in the Pharmaceutical Candidate Optimization (PCO) department that encompasses broad support for Discovery programs and has a diverse range of expertise in DMPK, toxicology, pharmaceutics and bioanalytical sciences.

In this role, the selected candidate will provide subject matter expertise on absorption, distribution, metabolism and excretion (ADME) and pharmacokinetic-pharmacodynamic (PK-PD) modeling in support of Discovery projects. He or she will be expected to take mechanistic approaches and conduct relevant experiments to understand drug disposition profiles and PK-PD relationships for issue resolution, program advancement and translation of dosage regimens from preclinical to clinical. The individual will represent the DMPK group in Discovery project teams and contribute to program science and strategies across the Discovery portfolio.

Qualifications & Experience:

* Ph.D. in pharmacokinetics, drug metabolism or related discipline

* 5 years of relevant industrial experience

* A deep understanding of DMPK and PK-PD principles is essential to this job

* Demonstrated problem-solving skills, critical thinking ability on hypothesis generation, and capability of integrating data in a quantitative manner are required

* Hands-on experience in conducting in vitro and/or in vivo experiments is desired; experience in modeling and simulation is a plus

* Strong communication skills and ability to work and collaborate in a multi-discipline team setting are required for this role

Why You Should Apply:

Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.

Bristol-Myers Squibb

New York, New York

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.

The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.